Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v9-FR Version v1-EN
Language French English
Date Updated 2022-06-01 2022-04-28
Drug Identification Number 02242905 02242905
Brand name MIDAZOLAM INJECTION MIDAZOLAM INJECTION
Common or Proper name Midazolam Injection Midazolam Injection
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients MIDAZOLAM MIDAZOLAM
Strength(s) 5MG 5MG
Dosage form(s) LIQUID LIQUID
Route of administration INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR
Packaging size 2mL 2mL
ATC code N05CD N05CD
ATC description HYPNOTICS AND SEDATIVES HYPNOTICS AND SEDATIVES
Reason for shortage Disruption of the manufacture of the drug. Delay in shipping of the drug.
Anticipated start date
Actual start date 2022-05-01 2022-05-01
Estimated end date 2022-06-03 2022-06-03
Actual end date 2022-03-31
Shortage status Avoided shortage Anticipated shortage
Tier 3 Status No No
Company comments Fresenius Kabi Canada regrets to advise that due to production delays, we will be experiencing supply interruptions. During our supply interruption on Midazolam Injection 5 mg/mL MD Vial 2 mL, our Midazolam Injection 5 mg/mL MD Vial 10 mL will be available for substitution. Fresenius Kabi Canada regrets to advise that due to shipping delays, we will be experiencing supply interruptions
Health Canada comments